Subsidiary Sunway Biotech to Acquire Weider Global Nutrition Acquisition Completes Bora Group's Dual-Engine Growth Strategy Across Entities
Bora Pharmaceuticals Co., Ltd. (“Bora”; TWSE: 6472; OTCQX: BORAY) announced that the Board of Directors of its subsidiary Sunway Biotech Co., Ltd. (TWSE: 1271, “Sunway”) has approved the acquisition of 100% of Weider Global Nutrition (“WGN”), an iconic American sports nutrition brand headquartered in Phoenix, Arizona. The transaction follows Sunway’s strategic investment in Wonders Company Ltd. in August 2025 and represents a deliberate transformation toward owning high-value distribution assets and exploring nutraceutical substance CDMO opportunities. Key channel assets to be acquired include a strategic supplier relationship with U.S. Costco, a commercial presence across more than 60 countries, and established e-commerce positions on Amazon and Walmart. The acquisition is expected to position Sunway among the top three nutraceutical brand groups in Taiwan, creating a platform from which to pursue further consolidation, expand into adjacent nutraceutical substance CDMO categories, and unlock distribution synergies across the Group’s existing commercial footprint. Financing will be provided through a combination of debt and equity and investors include Bora Pharmaceuticals, WTT Investment Family Office, and WGN CEO Rick Blair. The Board has authorized the Chairman to execute closing.
Bora Group and Sunway Chairman Bobby Sheng noted that the industry is at an inflection point: “The nutraceutical sector has historically scaled through pharmaceutical vertical integration and PE-driven brand consolidation and yet the next wave will be won on science. Consumer expectations are shifting, with clinical efficacy now the top purchasing criterion for a growing share of buyers globally. Monacolin K has just been restricted in the EU on cardiovascular safety grounds, which directly benefits our core proprietary ingredient, Ankascin 568 – the only red yeast rice product worldwide with U.S. FDA New Dietary Ingredient (NDI) status that is free of Monacolin K. We see a clear opportunity to combine validated science with WGN’s existing distribution infrastructure to capture that growth. WGN’s demonstrated commercial reach across global markets is expected to materially reorient Sunway’s revenue mix and establish a top and bottom-line accretive growth driver.”
He further highlighted Sunway’s fully enclosed solid-state fermentation platform, in which sterilization, fermentation, drying, and collection is fully automated within a sealed system. “The process consistency delivered is commercially significant and comes with high technical entry barrier. At Bora, we have been building synergies with dual engine strategy where our manufacturing capabilities serve internal clients such as Upsher-Smith. With acquisition of Weider, we expect to apply similar growth rationale: Sunway’s production infrastructure and Weider’s brand equity are complementary assets that, combined, strengthen the Bora Group’s overall competitive position.” Co-branded products under the Ankascin and Weider labels are targeted for launch in Europe in late 2026. Clinical trials supporting functional claims in certain markets are currently in progress with the objective of accessing mainstream retail as well.